← Leaderboards
Clifton Barry
Niaid Extramural Activities
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisDrug ResistanceLaboratory MouseIsoniazidMicroorganism MetabolismHigh Performance Liquid ChromatographyNuclear Magnetic Resonance SpectroscopyDrug Design /Synthesis /ProductionCell WallHydroxy Fatty AcidGas Chromatography Mass SpectrometryPharmacokineticsScientistBacterial ProteinsAntitubercular AgentsPolymerase Chain ReactionGel ElectrophoresisFatty Acid SynthaseAnalogEnzyme InhibitorsEnzyme ActivityInfectionLiquid Chromatography Mass Spectrometry
Grant awards (27)
Exploring the metabolism of non-replicating and drug-resistant TB$1,400,592
Z01 · FY2008 · AI · contact PI
Development Of New Chemotherapeutics For Tuberculosis$1,288,544
Z01 · FY2008 · AI · contact PI
Experimental Animal Models of TB: Chemotherapeutics and Imaging$1,232,521
Z01 · FY2008 · AI · contact PI
Development Of New Chemotherapeutics For Tuberculosis$6,811,260
Z01 · FY2007 · AI · contact PI
Pathogenesis, Latency and Drug Resistance Of Mycobacterium Tuberculosis$4,355,662
Z01 · FY2007 · AI · contact PI
Experimental Tb Chemotherapeutics: Animal Models And Clinical Evaluation$3,829,709
Z01 · FY2007 · AI · contact PI
Experimental Tb Chemotherapeutics: Animal Models And Cli$0
Z01 · FY2006 · AI · contact PI
Development Of New Chemotherapeutics For Tuberculosis$0
Z01 · FY2006 · AI · contact PI
Pathogenesis, Latency and Drug Resistance Of Mycobacteri$0
Z01 · FY2006 · AI · contact PI
Pathogenesis And Latency Of Mycobacterium Tuberculosis$0
Z01 · FY2005 · AI
Development Of New Chemotherapeutics For Tuberculosis$0
Z01 · FY2005 · AI
TB Chemotherapeutics--Animal Models &Mode of Action$0
Z01 · FY2005 · AI
Pathogenesis And Latency Of Mycobacterium Tuberculosis$0
Z01 · FY2004 · AI
Development Of New Chemotherapeutics For Tuberculosis$0
Z01 · FY2004 · AI
Experimental Tb Chemotherapeutics: Animal Models And Mod$0
Z01 · FY2004 · AI
Pathogenesis And Latency Of Mycobacterium Tuberculosis$0
Z01 · FY2003 · AI
Development Of New Chemotherapeutics For Tuberculosis$0
Z01 · FY2003 · AI
Experimental Tb Chemotherapeutics: Animal Models And Mod$0
Z01 · FY2003 · AI
Development Of New Chemotherapeutics For Tuberculosis$0
Z01 · FY2002 · AI
Experimental Tb Chemotherapeutics: Animal Models And Mod$0
Z01 · FY2002 · AI
Pathogenesis And Latency Of Mycobacterium Tuberculosis$0
Z01 · FY2002 · AI
Mechanisms Of Antituberculosis Chemotherapeutics$0
Z01 · FY2001 · AI
Mechanisms Of Cell Wall Biogenesis Of Tuberculosis$0
Z01 · FY2001 · AI
Metabolic Strategies Of In Vivo And Latent Mycobacterium$0
Z01 · FY2001 · AI
Mechanisms of Antituberculosis Chemotherapeutics$0
Z01 · FY2000 · AI
Metabolic strategies of in vivo and latent Mycobacterium tuberculosis$0
Z01 · FY2000 · AI
Mechanisms of cell wall biogenesis of Mycobacterium tuberculosis$0
Z01 · FY2000 · AI